Search results for "ABO"

showing 10 items of 13628 documents

In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy

2004

LDL can be subfractionated into buoyant (1.020-1.029 g/ml(-1)), intermediate (1.030-1.040 g/ml(-1)), and dense (1.041-1.066 g/ml(-1)) LDLs. We studied the rebound of these LDL-subfractions after LDL apheresis in seven patients with heterozygous familial hypercholesterolemia (FH) regularly treated by apheresis (58 +/- 9 years, LDL-cholesterol = 342 +/- 87 mg/dl(-1), triglycerides = 109 +/- 39 mg/dl(-1)) and high-dose statins. Apolipoprotein B (apoB) concentrations were measured in LDL subfractions immediately after and on days 1, 2, 3, 5, and 7 after apheresis. Compartmental models were developed to test three hypotheses: 1) that dense LDLs are derived from the delipidation of buoyant and in…

medicine.medical_specialtyVery low-density lipoproteinApolipoprotein Blow density lipoprotein metabolismFamilial hypercholesterolemiaQD415-436Biochemistrychemistry.chemical_compoundEndocrinologyInternal medicinerebound kineticsmedicinesmall dense low density lipoproteinsdensity gradient ultracentrifugationbiologyfamilial hypercholesterolemiaChemistryCholesterollow density lipoprotein subtypesCell BiologyMetabolismmedicine.diseaseEndocrinologyApheresisLDL apheresisbiology.proteinDensity gradient ultracentrifugationlipids (amino acids peptides and proteins)Journal of Lipid Research
researchProduct

Statins and diabetes.

2005

Lipid abnormalities play an important part in raising the cardiovascular risk in diabetic subjects. The main components of diabetic dyslipidemia are increased plasma triglycerides, low concentration of high-density lipoprotein cholesterol, preponderance of small, dense low-density lipoprotein, and excessive postprandial lipemia. Small, dense low-density lipoprotein, the elevation in remnant triglyceride-rich lipoprotein particles, and the low high-density lipoprotein are the most powerful atherogenic components. The coexistence of these three factors strongly aggravates the lipid accumulation in the arterial wall and the formation of atherosclerotic plaques. The position of diabetes in card…

medicine.medical_specialtyVery low-density lipoproteinHyperlipidemiasType 2 diabeteschemistry.chemical_compoundInsulin resistanceRisk FactorsInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumansTriglyceridebusiness.industrymedicine.diseaseLipidsEndocrinologychemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Therapeutic Lifestyle ChangesMetabolic syndromeHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessLipoproteinSeminars in vascular medicine
researchProduct

Dietary cholate increases plasma levels of apolipoprotein B in mice by posttranscriptional mechanisms

2001

To induce atherogenesis in mice, a high fat (HF) diet is supplemented with cholic acid (CA), which increases apoB-containing particles and lower apoA-I-containing particles. HF diet without CA increases levels of both HDL and LDL, suggesting that CA may be responsible for the elevation of LDL and lowering of HDL. The mechanism of dietary CA-induced lowering of apoA-I-containing particles has recently been reported. In this study, we examined the mechanism of CA- and HF-induced elevation of apoB-containing lipoproteins in mice. Mice were fed the following four diets: control chow (C), high fat high cholesterol, (HF), control and 0.5% cholate (CA), and HF + CA. Dietary CA increased the plasma…

medicine.medical_specialtyVery low-density lipoproteinSettore MED/09 - Medicina InternaMouseApolipoprotein Bmedicine.medical_treatmentDown-RegulationCholic AcidLipoproteins VLDLBiochemistryDietary cholateMicechemistry.chemical_compoundApolipoproteins ERibonucleasesDownregulation and upregulationInternal medicinemedicineAnimalsVitamin ERNA MessengerRNA Processing Post-TranscriptionalReceptorApolipoproteins BbiologyChemistryVitamin ECholic acidnutritional and metabolic diseasesCell BiologyBlotting NorthernDietLipoproteins LDLMice Inbred C57BLCholesterolEndocrinologyLiverReceptors LDLLDL receptorbiology.proteinlipids (amino acids peptides and proteins)Gene expressionHepatic lipaseApolipoprotein BCholatesDietary fatThe International Journal of Biochemistry & Cell Biology
researchProduct

Statins and metabolic syndrome

2003

Abstract Metabolic syndrome (MS) is a multifactorial condition that represents a risk factor for the development of diabetes mellitus (DMII) and cardiovascular disease (CVD). Statins may play a role on some modifiable clinical features of MS; in fact, whereas therapeutic lifestyle changes are mandatory for MS with a 10-year coronary heart disease (CHD) risk 20% and to correct the other associated lipid and non-lipid abnormalities. In fact, they have a VLDL lowering action in hypertriglyceridemia, they reduce the amount of small and dense LDL, they increase the HDL-C, they reduce the atherogenic lipoproteins, and they decrease the inflammatory marker levels.

medicine.medical_specialtyVery low-density lipoproteinbusiness.industryHypertriglyceridemianutritional and metabolic diseasesGeneral MedicineDiseasemedicine.diseaseEndocrinologyDiabetes mellitusInternal medicinemedicineCardiologylipids (amino acids peptides and proteins)RosuvastatinTherapeutic Lifestyle ChangesMetabolic syndromeRisk factorbusinessmedicine.drugInternational Congress Series
researchProduct

Obesity prevalence in Norwegian adults assessed by body mass index, waist circumference and fat mass percentage

2015

The prevalence of obesity presents serious public health challenges worldwide and is most commonly estimated by the categorization of body mass index (BMI). The purpose of this study was (i) to describe the sensitivity of BMI, waist circumference (WC) and fat mass percentage in the classification of overweight and obesity and (ii) to describe the prevalence of overweight and obesity using different measurement methods in a national sample of Norwegians. A total of 904 Norwegians (20-85 years) were randomly enrolled. Body weight, height, WC and skinfold thickness were measured; BMI and fat mass percentage (FP(skf) ) were calculated. The sensitivity and specificity varied from 77.0% to 86.9% …

medicine.medical_specialtyWaistBody volume indexbusiness.industryEndocrinology Diabetes and MetabolismPrevalenceOverweightmedicine.diseaseObesityConfidence intervalEndocrinologyClassification of obesityInternal medicinemedicinemedicine.symptombusinessBody mass indexDemographyClinical Obesity
researchProduct

A Combined Multidisciplinary Intervention for Health Promotion in the Workplace: A Pilot Study

2021

The aim of this study was to assess the effects of a joint health promotion intervention on a cohort of healthcare workers (HCWs) who had at least one cardiovascular risk factor. The HCWs were assessed at three different times, i.e., time zero (T0), after 6 months (T6), and after 12 months (T12). The following parameters were measured at a medical examination: physical activity, blood pressure, waist circumference, body mass index (BMI), routine laboratory tests, plicometric analysis, work ability index (WAI), and body image dissatisfaction (BID). Among the 447 HCWs, 38 HCWs were included in the study; 45% (n = 17) were male. At T12, the average blood pressure, waist/hip ratio (WHR) index, …

medicine.medical_specialtyWaistMediterranean diethealth care facilities manpower and serviceseducationlcsh:Medicine030209 endocrinology & metabolismArticle03 medical and health sciences0302 clinical medicineWorkplace health promotionMediterranean dietHealth careMedicinecardiovascular risk factorbody image dissatisfaction (BID)030212 general & internal medicineRisk factorbusiness.industryhealthcare workerslcsh:Rvirus diseasesGeneral Medicinework ability index (WAI)Health promotionworkplace health promotion; healthcare workers; cardiovascular risk factor; work ability index (WAI); Mediterranean diet; body image dissatisfaction (BID)CohortHealthcare workerPhysical therapyworkplace health promotionbusinessBody mass indexJournal of Clinical Medicine
researchProduct

A tailored telephone and email based exercise intervention induced reductions in various measures of body composition in physically inactive adults: …

2018

Obesity prevalence has increased the past decades and has become a serious public health problem. The aim of this six-month assessor-blinded, parallel-group randomized controlled trial was to assess the effect of a tailored telephone and email-based exercise intervention on various measures of body composition in a sample of apparently healthy and physically inactive adults. A total of 111 volunteering adults (40–55 yr) in Southern Norway were randomly assigned to an intervention group (IG; n = 39) or a no-information control group (CG; n = 50), by random allocation numbering. The IG received feedback on their health-related physical fitness, information on guidelines and recommendations fo…

medicine.medical_specialtyWaistPhysical fitnesslcsh:Medicine030209 endocrinology & metabolismHealth InformaticsBody compositionlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawIntervention (counseling)medicine030212 general & internal medicineCG Control GroupCRF cardiorespiratory fitnessbusiness.industryPublic healthWC Waist Circumferencelcsh:RWeight changeWeight changePublic Health Environmental and Occupational HealthRegular Articlemedicine.diseaseObesityIG Intervention GroupPhysical therapyFPskf Fat Percentage by skinfoldsBMI Body Mass IndexbusinessMixed delivery modesBody mass indexPreventive Medicine Reports
researchProduct

Improved Cardiovascular and Cardiometabolic Risk in Patients With Type 1 Diabetes and Autoimmune Polyglandular Syndrome Switched From Glargine to Deg…

2018

Background: Cardiovascular disease is a frequent complication of type 1 diabetes (T1D). We evaluated the effectiveness of switching from glargine to degludec in reducing the cardiovascular risk factors, the Framingham risk score (FRS) and visceral adiposity index (VAI) in patients with T1D and autoimmune polyglandular syndrome (APS).Methods: We selected 66 T1D outpatients who had been on stable treatment with glargine for at least 5 years. Among them, 30 patients maintained glargine (group A), while 36 were switched to degludec (group B) for 12 months. At baseline and after 12 months of observation, clinical and metabolic parameters, insulin dose, 30-days blood glucose (BG) self monitoring,…

medicine.medical_specialtyWaistType 1 diabetetype 1 diabetesmedicine.medical_treatmentEndocrinology Diabetes and Metabolism030209 endocrinology & metabolism030204 cardiovascular system & hematologyGroup AGastroenterologylcsh:Diseases of the endocrine glands. Clinical endocrinologyGroup BSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicinemedicineIn patientGlargineOriginal ResearchType 1 diabetesFramingham Risk Scorelcsh:RC648-665business.industryInsulinmedicine.diseaseCardiovascular riskInsulin therapyComplicationbusinessHypoglycaemiaDegludecFrontiers in Endocrinology
researchProduct

Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population.

2003

Background: Our objective was to investigate the relationship between abdominal obesity (AO), as measured by waist circumference (WC), insulin resistance (IR), and components of the metabolic syndrome (MS). Methods: A cross-sectional study was carried out with 283 subjects (130 males and 153 females aged 25–65 years) from a primary care outpatient clinic in Valencia (Spain) over a period of 1 year. Body mass index (BMI), waist circumference (WC), blood pressure (BP), total cholesterol, triglycerides, HDL-C, glucose, and insulin were measured by standard methods. IR was defined as HOMA-IR equal to or greater than 3.8. Results: The prevalence of IR was 39.6%. Subjects were divided into groups…

medicine.medical_specialtyWaistbusiness.industryOdds ratiomedicine.diseaseObesityEndocrinologyInsulin resistanceInternal medicineInternal MedicineMedicineOutpatient clinicMetabolic syndromemedicine.symptombusinessBody mass indexAbdominal obesityEuropean journal of internal medicine
researchProduct

Predictive factors of polycystic ovary syndrome in girls with precocious pubarche

2021

Objective: The aim of this study is to clarify, in girls with premature pubarche (PP), the influence of premature androgenization on the prevalence of polycystic ovary syndrome (PCOS). Design and patients: Ninety-nine PP girls, 63 who developed PCOS and 36 who did not develop PCOS, were retrospectively included. Clinical, anthropometric, and metabolic parameters were evaluated at the time of diagnosis of PP and after 10 years from menarche to find predictive factors of PCOS. Results: Young females with PP showed a PCOS prevalence of 64% and showed a higher prevalence of familial history of diabetes (P = 0.004) and a lower prevalence of underweight (P = 0.025) than PP-NO-PCOS. In addition, g…

medicine.medical_specialtyWaistendocrine system diseasesEndocrinology Diabetes and MetabolismDiseases of the endocrine glands. Clinical endocrinologySettore MED/13 - EndocrinologiahyperandrogenismEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusinsulin resistanceInternal MedicinemedicineHyperandrogenism .insulin resistancebusiness.industryResearchHyperandrogenismdyslipidemianutritional and metabolic diseasesvisceral obesitymedicine.diseaseRC648-665Polycystic ovaryEndocrinologyMenarcheUnderweightmedicine.symptomprecocious menarchebusinessDyslipidemiaEndocrine Connections
researchProduct